Profile of drugs used in patients with covid-19 in two hospitals in santa catarina

Abstract

Introduction: the first reports of the disease caused by SARS-Cov-2 emerged in Wuhan, China in late 2019, and the causative agent and its ability to cause pneumonia, respiratory failure, and eventually death were soon identified more clearly. Based on the accurate study of the disease, several studies have emerged in an attempt to find a treatment, and there are currently more than 4,000 clinical studies related to the subject. Objectives: to perform a data research regarding the main drugs used in patients with COVID-19 in two hospitals in Santa Catarina, using these data to improve care. Method: a retrospective analysis of 683 medical records of patients admitted to infirmary and ICU beds in two hospitals in Santa Catarina. Results: in our study, high rates of antimicrobial use were observed, especially ceftriaxone and azithromycin, among the glucocorticoids dexamethasone was the most commonly used, anti-coagulant in varying doses was also common, other drugs such as hydroxychloroquine, ivermectin and hydrocortisone had lower rates of use. Discussion: currently the only drug with evidence of benefit in the outcome of mortality is dexamethasone when used in patients with moderate to severe symptoms, the other drugs should follow precise indications to have their use rationalized. Conclusion: to date, we still do not have a specific and effective therapy that results in clinical benefit in all cases of COVID-19, however, several drugs are still being tested, therefore, it is up to us to wait and act according to the current evidence.